Interleukin-10 promotes the maintenance of antitumor CD8+ T-cell effector function in situ

Blood

Volumn 98, Issue 7, 2001, Pages 2143-2151

  Fujii, Shin Ichiro ^a,b   Shimizu, Kanako ^a   Shimizu, Takashi ^a   Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; HERMES ANTIGEN; INTERLEUKIN 2 RECEPTOR BETA; RECOMBINANT INTERLEUKIN 10; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CELL COUNT; CELL FUNCTION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXICITY; DENDRITIC CELL; DRUG DESIGN; DRUG EFFICACY; FEMALE; IMMUNE RESPONSE; IMMUNOBIOLOGY; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY; VACCINATION;

EID: 0035496946     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.7.2143     Document Type: Article

References (53)

1. Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood. 1997;89:3129-3135.
2. Nelson EL, Li X, Hsu FJ, et al. Tumor-specific, cytotoxic T-lymphocyte response after idiotype vaccination for B-cell, non-Hodgkin's lymphoma. Blood. 1996;88:580-589.
3. + cord blood cell-derived and irradiated tumor cell-primed dendritic cells. Int J Hematol. 1998;68:169-182.
4. + hematopoietic progenitor cells: induction of autologous cytotoxic T lymphocytes against leukemic cells in acute myelogenous leukemia patients. Cancer Res. 1999;59:2150-2158.
5. Fujii S-I, Hamada H, Fujimoto K, Shimomura T, Kawakita M. Activated dendritic cells from bone marrow cells of mice receiving cytokine-expressing tumor cells are associated with the enhanced survival of mice bearing syngeneic tumors. Blood. 1999;93:4328-4335.
6. Fujii S-I, Shimizu K, Fujimoto K, et al. Analysis of a chronic myelogenous leukemia patient vaccinated with leukemic dendritic cells following autologous peripheral blood stem cell transplantation. Jpn J Cancer Res. 1999;90:1117-1129.
7. Murali-Krishna K, Altman JD, Suresh M, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity. 1998;8:177-187.
8. Fujii S-I. The interaction between interferon-α and clonally expanded T cells in chronic myelogenous leukemia (CML). Leuk Lymphoma. 2000;38:21-38.
9. + T cells in vivo by IL-15. Immunity. 1998;8:591-599.
10. + memory T cells by opposing cytokines. Science. 2000;288:675-678.
11. Marrack P, Kappler J, Mitchell T. Type-I interferons keep activated T cells alive. J Exp Med. 1999;189:521-530.
12. Ahmed R, Gray D. Immunological memory and protective immunity: understanding their relation. Science. 1996;272:54-66.
13. McHeyzer-Williams MG, Davis MM. Antigen-specific development of primary and memory T cells in vivo. Science. 1995;268:106-111.
14. Cerwenka A, Morgan TM, Dutton RW. Naive, effector, and memory CD8 T cells in protection against pulmonary influenza virus infection: homing properties rather than initial frequencies are crucial. J Immunol. 1999;163:5535-5543.
15. MacDonald KPA, Pettit AR, Quinn C, Thomas GJ, Thomas R. Resistance of rheumatoid synovial dendritic cells to the immunosuppressive effects of IL-10. J Immunol. 1999;63:5599-5607.
16. + T cells. J Immunol. 1998;160:3188-3193.
17. Hagenbaugh A, Sharma S, Dubinett SM, et al. Altered immune responses in interleukin-10 transgenic mice. J Exp Med. 1997;185:2101-2110.
18. de Waal Malefyt R, Yssel H, de Varies JE. Direct effects of IL-10 on subsets of human CD4 T cell clones and resting T cells: specific inhibition of IL-2 production and proliferation. J Immunol. 1993;150:4754-4765.
19. Taga K, Mostowski H, Tosato G. Human interleukin-10 can directly inhibit T-cell growth. Blood. 1993,81:2964-2971
20. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-related dendritic cells. J Immunol. 1997;159:4772-4780.
21. + T cells resulting in a failure to lyse tumor cells. Blood. 1999;93:1634-1642.
22. Taga K, Cherney B, Tosato G. Interleukin-10 inhibits apoptotic cell death in human T cells starved of IL-2. Int Immunol. 1993;5:1599-1608.
23. Cohen SB, Crawley JB, Kaharn MC, Foldman M, Foxwell MB. Interleukin-10 rescues T cells from apoptotic cell death: association with an up-regulation of bcl-2. Immunology. 1997;92:1-5.
24. Qian S, Li W, Li Y, et al. Systemic administration of cellular interleukin-10 can exacerbate cardiac allograft rejection in mice. Transplantation. 1996; 62:1709-1714.
25. + T cell-mediated graft-versus-host disease. Transplantation. 1998,66:1220-1229.
26. Groux H, Cottrez F, Rouleau M, et al. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol. 1999;162:1723-1729.
27. Berman RM, Suzuki T, Tahara H, Robbin PD, Narula SK, Lotze MT. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J Immunol. 1996;157:231-238.
28. Cervenak L, Morbidelli L, Donati D, et al. Abolished angiogenicity and tumorigenicity of Burkitt lymphoma by interleukin-10. Blood. 2000;96: 2568-2573.
29. Zheng LM, Ojcius DM, Roth FGC, et al. Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med. 1996; 184:579-584.
30. Hiroishi K, Tuting T, Lotze MT. IFN-alpha-expressing tumor cells enhance generation and promote survival of tumor-specific CTLs. J Immunol. 2000;164:567-572.
31. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity. J Exp Med. 1996;183:283-287.
32. Porgador A, Gilboa E. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med. 1995;182:255-260.
33. + T cell responses. Curr Opin Immunol. 2000;12:448-455.
34. Asseman C, Mauze S, Leach MW, Coffman RL, Powrie F. An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med. 1999;7:995-1003.
35. Shibata Y, Foster LA, Kurimoto M, et al. Immunoregulatory roles of IL-10 in innate immunity: IL-10 inhibits macrophage production of IFN-γ-inducing factors but enhances NK cell production of IFN-γ. J Immunol. 1998;161:4283-4288.
36. -) to TCR/CD8 signaling in response to antigen. J Immunol. 1998;160:3236-3243.
37. + T cells can be distinguished by their cytokine profiles and phenotypic markers. J Immunol. 2000;164:208-216.
38. Sigal LJ, Crotty S, Andino R, Rock KL. Cytotoxic T-cell immunity to virus-infected non-hematopoietic cells requires presentation of exogenous antigen. Nature. 1999;398:77-80.
39. Murali-Krishna K, Lau LL, Sambhara S, Lemonnier F, Altman J, Ahmed R. Persistence of memory CD8 T cells in MHC class I-deficient mice. Science. 1999;286:1377-1383.
40. Jacob J, Baltimore D. Modelling T-cell memory by genetic marking of memory T cells in vivo. Nature. 1999;399:593-597.
41. + memory T cells. J Exp Med. 1997;186:859-865.
42. Rogers PR, Dubey C, Swain SL. Qualitative changes accompany memory T cell generation: faster, more effective responses at lower doses of antigen. J. Immunol. 2000;164:2338-2346.
43. + cytotoxic T lymphocytes. J. Exp. Med. 1998;187:49-57.
44. Pawelec G, Hambrecht A, Rehbein A, Adibzadeh M. Interleukin-10 protects activated human T lymphocytes against growth factor with draw-induced cell death but only anti-fas antibody can prevent activation-induced cell death. Cytokine. 1996;8: 877-881.
45. + CTL primed by exogenous antigens. J Immunol. 2000;164:5698-5703.
46. Opferman JT, Ober BT, Ashton-Rickardt PG. Linear differentiation of cytotoxic effectors into memory T lymphocytes. Science. 1999;283:1745-1748.
47. + T cells, but not B cells, mediate colitis in interleukin-10-deficient mice. J Exp Med. 1996;184:241-251.
48. Di Somma MM, Somma F, Saveria M, et al. TCR engagement regulates differential responsiveness of human memory T cells to Fas (CD95)-mediated apoptosis. J Immunol. 1999;162:3851-3858.
49. Wei CH, Yagita H, Masucci MG, Levitsky V. Different programs of activated-induced cell death are triggered in mature activated CTL by immunogenic and partially agonistic peptide ligands. J Immunol. 2001;166:989-995.
50. Salvucci O, Carsana M, Bersani I, Tragni G, Anichini A. Antiapoptotic role of endogenous nitric oxide in human melanoma cells. Cancer Res. 2001;61:318-326.
51. + T cells. J Exp Med. 1996;184:19-29.
52. Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell. 2000;101: 455-458.
53. + T cells. J Immunol. 1998;160:3188-3193.